Answers are grounded in this paper and cite their sources.
Prostate-specific membrane antigen (PSMA)-targeted radioguided surgery (RGS) is evolving as a new treatment modality for patients with early biochemical recurrence of prostate cancer and disease limited to locoregional lymph nodes on PSMA-ligand PET/CT. Nevertheless, the pattern of failure (locoregional vs. systemic) after PSMA RGS remains unknown. Therefore, the aim of this retrospective analysis was to evaluate the pattern of disease using PSMA-ligand PET in patients experiencing relapse after PSMA RGS.
No takes yet. Share an insight, caveat, or question.
Schweiger et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: